$ABBV (-0,38 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway
$BMY (-1,43 %) Bristol-Myers Squibb seems to benefits from this +13%
$ABBV (-0,38 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway
$BMY (-1,43 %) Bristol-Myers Squibb seems to benefits from this +13%